Cidara’s pipeline comprises new approaches aimed at transforming existing treatment and prevention paradigms, leveraging its highly potent, long-acting drug-Fc conjugates (DFCs) from its proprietary Cloudbreak® platform that target viral and oncology disease areas, followed by its once-weekly antifungal candidate, rezafungin.